142 related articles for article (PubMed ID: 9085405)
1. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks.
van Megen HJ; Westenberg HG; den Boer JA; Slaap B; Scheepmakers A
Psychopharmacology (Berl); 1997 Feb; 129(4):357-64. PubMed ID: 9085405
[TBL] [Abstract][Full Text] [Related]
2. The panic-inducing properties of the cholecystokinin tetrapeptide CCK4 in patients with panic disorder.
van Megen HJ; Westenberg HG; Den Boer JA; Kahn RS
Eur Neuropsychopharmacol; 1996 Aug; 6(3):187-94. PubMed ID: 8880078
[TBL] [Abstract][Full Text] [Related]
3. CCK4-induced panic in healthy subjects I: psychological and cardiovascular effects.
Jerabek I; Boulenger JP; Bradwejn J; Lavallée YJ; Jolicoeur FB
Eur Neuropsychopharmacol; 1999 Jan; 9(1-2):149-55. PubMed ID: 10082241
[TBL] [Abstract][Full Text] [Related]
4. The effect of 6-week treatment with escitalopram on CCK-4 challenge: a placebo-controlled study in CCK-4-sensitive healthy volunteers.
Tõru I; Maron E; Raag M; Vasar V; Nutt DJ; Shlik J
Eur Neuropsychopharmacol; 2013 Jul; 23(7):645-52. PubMed ID: 22939006
[TBL] [Abstract][Full Text] [Related]
5. The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients.
van Megen HJ; Westenberg HG; den Boer JA; Slaap B; van Es-Radhakishun F; Pande AC
Psychopharmacology (Berl); 1997 Feb; 129(3):243-8. PubMed ID: 9084062
[TBL] [Abstract][Full Text] [Related]
6. Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram.
Tõru I; Shlik J; Maron E; Vasar V; Nutt DJ
Psychopharmacology (Berl); 2006 May; 186(1):107-12. PubMed ID: 16541242
[TBL] [Abstract][Full Text] [Related]
7. Effect of fluvoxamine on panic disorder.
Hoehn-Saric R; McLeod DR; Hipsley PA
J Clin Psychopharmacol; 1993 Oct; 13(5):321-6. PubMed ID: 8227490
[TBL] [Abstract][Full Text] [Related]
8. CCK4-induced panic in healthy subjects II: neurochemical correlates.
Jerabek I; Boulenger JP; Bradwejn J; Drumheller A; Lavallée YJ; Jolicoeur FB
Eur Neuropsychopharmacol; 1999 Jan; 9(1-2):157-64. PubMed ID: 10082242
[TBL] [Abstract][Full Text] [Related]
9. Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder.
Ströhle A; Holsboer F; Rupprecht R
Neuropsychopharmacology; 2000 Mar; 22(3):251-6. PubMed ID: 10693152
[TBL] [Abstract][Full Text] [Related]
10. Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings.
Wiedemann K; Jahn H; Yassouridis A; Kellner M
Arch Gen Psychiatry; 2001 Apr; 58(4):371-7. PubMed ID: 11296098
[TBL] [Abstract][Full Text] [Related]
11. Biological dissection of anxiety disorders: the clinical role of selective serotonin reuptake inhibitors with particular reference to fluvoxamine.
den Boer JA; Westenberg HG; De Leeuw AS; van Vliet IM
Int Clin Psychopharmacol; 1995 Jan; 9 Suppl 4():47-52. PubMed ID: 7622824
[TBL] [Abstract][Full Text] [Related]
12. Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients.
Asnis GM; Hameedi FA; Goddard AW; Potkin SG; Black D; Jameel M; Desagani K; Woods SW
Psychiatry Res; 2001 Aug; 103(1):1-14. PubMed ID: 11472786
[TBL] [Abstract][Full Text] [Related]
13. Distinct panicogenic activity of sodium lactate and cholecystokinin tetrapeptide in patients with panic disorder.
Plag J; Gaudlitz K; Zschucke E; Yassouridis A; Pyrkosch L; Wittmann A; Holsboer F; Ströhle A
Curr Pharm Des; 2012; 18(35):5619-26. PubMed ID: 22632477
[TBL] [Abstract][Full Text] [Related]
14. Functional neuroanatomy of CCK4-induced anxiety in normal healthy volunteers.
Benkelfat C; Bradwejn J; Meyer E; Ellenbogen M; Milot S; Gjedde A; Evans A
Am J Psychiatry; 1995 Aug; 152(8):1180-4. PubMed ID: 7625467
[TBL] [Abstract][Full Text] [Related]
15. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin.
Den Boer JA; Westenberg HG
Psychopharmacology (Berl); 1990; 102(1):85-94. PubMed ID: 1697419
[TBL] [Abstract][Full Text] [Related]
16. Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder.
Goddard AW; Woods SW; Sholomskas DE; Goodman WK; Charney DS; Heninger GR
Psychiatry Res; 1993 Aug; 48(2):119-33. PubMed ID: 8416022
[TBL] [Abstract][Full Text] [Related]
17. Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses.
Abelson JL; Nesse RM
Biol Psychiatry; 1994 Jul; 36(2):73-83. PubMed ID: 7948449
[TBL] [Abstract][Full Text] [Related]
18. Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients.
van Megen HJ; Westenberg HG; den Boer JA; Haigh JR; Traub M
Psychopharmacology (Berl); 1994 Apr; 114(3):449-55. PubMed ID: 7855203
[TBL] [Abstract][Full Text] [Related]
19. A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder.
van Vliet IM; den Boer JA; Westenberg HG; Slaap BR
J Clin Psychopharmacol; 1996 Aug; 16(4):299-306. PubMed ID: 8835705
[TBL] [Abstract][Full Text] [Related]
20. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder.
Bradwejn J; Koszycki D; Couëtoux du Tertre A; van Megen H; den Boer J; Westenberg H
Arch Gen Psychiatry; 1994 Jun; 51(6):486-93. PubMed ID: 8192551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
